

ISB'S Front-end PRIA Completeness Screen

Draft 3; 10/25/07

EPA Receipt Date: FEB 12 2009		EPA Reg. Number: 100-1207		
	Check List Item	Yes	No	N/A
1	Has the PRIA Fee been Paid ; is a copy of the check or Pay.gov receipt included in the Submission Package?	X		
2	Is an Application Form (EPA Form 8570-1) Included in the Submission Package, is it completely filled out and signed including package type?	X		
3	Is a Confidential Statement of Formula (EPA Form 8570-29) Included in the Submission Package, is it completely filled out and signed (boxes 1-21)?	X		
4	Is a Formulator's Exemption Statement (EPA Form 8570-27) Included in the Submission Package?		X	
5	Is a Certification with Respect to Citation of Data (EPA Form 8570-34) Included in the Submission Package?	X		
6	Is a Data Matrix (EPA Form 8570-35) Included in the Submission Package?	X		
7	Is a Label Included in the Submission Package?		X	
8	Are Data Included in the Submission Package?	X		
9	Is the Submission an Amendment?	X		

PRIA 2 - 21 Day Content Screen Review Worksheet

(EPA/OPP Use Only)

4/9/08

21 Day Screen Start Date: 2-12-09Experts In-Processing Signature: ME HARRINGTON Date 2-13-09 Fee Paid: Yes ☒Division management contacted on issues No ☐ Yes ☐ Date

EPA Reg. Number: <u>100-1207</u>		EPA Receipt Date: <u>2-12-09</u>			
Items for Review			Yes	No	N/A*
1	Application Form (EPA Form 8570-1) signed & complete including package type		X		
2	Confidential Statement of Formula all boxes completed, form signed, and dated (EPA Form 8570-4)		X		
	a) All inerts, except fragrances, approved for food and non food proposed uses (see Footnote A)	yes X	no		
3	Certification with Respect to Citation of Data (EPA Form 8570-34) completed and signed (N/A if 100% repack)		X		
	Certificate and data matrix consistent		X		
	If applicant is relying on data that are compensable, is the offer to pay statement included. (see Footnote B)	yes	no		
	If applicable, is there a letter of Authorization for exclusive use only.				
4	Formulator's Exemption Statement (EPA Form 8570-27) completed and signed (N/A if source is unregistered or applicant owns the technical)				X
	Data Matrix (EPA Form 8570-35) both internal and external copies (PR 98-5) completed and signed (N/A if 100% repack)		X		
5	a) Selective Method (Fee category experts use)	yes X	no		
	b) Cite-All (Fee category experts use)				
	c) Applicant owns all data (Fee category experts use)				
6	5 Copies of Label (Electronic labels on CD are encouraged)				X
7	Is the data package consistent with PR Notice 86-5		X		
8	Notice of Filing (link to included with petitions)				X

9	If applicable for conventional applications, reduced risk rationale				X
10	Required Data and/or data waivers. See Footnote C.				
	a) List study (or studies) not included with application				

Comments:

Passed 86-5
 MRID 476734
 1 study

MRID 476734

* N/A – Not Applicable

Footnotes

A. This consideration does not apply to PRIA applications that include a request to approve an inert in the fee category. For these PRIA actions, information needs to be submitted to enable the Agency to review the inert approval request and will be a subject of the 21 day content screen. For other types of actions and for fragrances, the answer is only for the Agency's information and current policies, processes, and procedures should be consulted. This worksheet will be updated in the future to be consistent with current policies.

If brand, trade, or proprietary names are being used for some inert ingredients listed on the CSF, alternate names or additional information on the nature of the ingredient(s) should be provided to allow the Agency to determine whether the inert has been approved.

B. A policy on documentation of offers to pay is still being developed, however, for a me-too or fast track (similar/identical) new product, R300 or A530, an application without the necessary authorizations of offers to pay will be placed into either R301 or A531. The Agency recommends that authorizations of offers to pay be submitted with other PRIA applications to avoid delays in the Agency's decision.

C. Refer to the list of data requirements. Biopesticide applicants were advised to contact the Agency and discuss study waivers prior to submitting their application to the Agency. Documentation of such discussions should be submitted with the study waiver.

MRID: 476734

PM: 25

**This submission is
Part of 21-day
Processing**

Reg. # 100 - 1207

**86-5 Compliance:
Passed/Failed**

21-day Expires

on 03/03/09

PM 25

100 - 1207